Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Reduce” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus rating of “Reduce” by the twelve research firms that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.20.

FULC has been the subject of several recent analyst reports. HC Wainwright downgraded Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Citigroup downgraded Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday, June 2nd. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a research note on Tuesday, June 2nd. Finally, Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC opened at $3.50 on Thursday. The business’s 50-day moving average is $6.32 and its two-hundred day moving average is $8.63. Fulcrum Therapeutics has a 12 month low of $2.83 and a 12 month high of $15.74. The firm has a market capitalization of $233.21 million, a PE ratio of -3.04 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. Equities analysts anticipate that Fulcrum Therapeutics will post -0.76 EPS for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter valued at approximately $164,000. Jane Street Group LLC raised its holdings in shares of Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after buying an additional 45,157 shares during the last quarter. Creative Planning bought a new stake in shares of Fulcrum Therapeutics during the second quarter valued at approximately $117,000. Legal & General Group Plc raised its holdings in shares of Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock valued at $120,000 after buying an additional 12,173 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after buying an additional 8,638 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.